Business
OncBioMune Provides Corporate Update; ASCO Reinforces Market Opportunity for New Prostate Cancer Vaccine as Phase 2 Trial Approaches
OncBioMune Provides Corporate Update; ASCO Reinforces Market Opportunity for New Prostate Cancer Vaccine as Phase 2 Trial Approaches.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\nOncBioMune Provides Corporate Update; ASCO Reinforces Market Opportunity for New Prostate Cancer Vaccine as Phase 2 Trial Approaches\n\nOncBioMune Provides Corporate Update; ASCO Reinforces Market Opportunity for New Prostate Cancer Vaccine as Phase 2 Trial Approaches\n\nBATON ROUGE, LA--(Marketwired - June 14, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (\"OncBioMune\" or the \"Company\"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today provides shareholders with an update on corporate and clinical developments.Mexican Trials of ProscaVax for Prostate CancerOncBioMune, with its joint venture partner Vitel Laboratorios S.A. de C.V. (\"Vitel\"), is near commencement of a Phase 2 clinical trial of the Company's novel cancer vaccine, ProscaVax, for the treatment of PSA (prostate specific antigen) recurrent prostate cancer in hormone-naïve and hormone-independent patients. Following successful meetings two weeks ago in Mexico with drug development authorities, parties involved in the upcoming Phase 2 trial and Vitel, OncBioMune executives have been invited next week to attend additional meetings with other scientists and venture capital funds interested in learning more about opportunities involving the trial and OncBioMune's vaccine technology platform.OncBioMune has also been advised that preparations for the Phase 2 trial are progressing smoothly and that patient screening and trial enrollment remains on target for the third quarter. We remain very encouraged by the support of the Mexican health authorities and guidance from Vitel that there is a clear path for expedited commercialization of ProscaVax if the trial can deliver results showing a meaningful therapeutic benefit of ProscaVax in reduction of PSA.\"The past few months have been very exciting for us as it seems that the investor and the scientific communities are really taking notice of how promising our vaccine technology is,\" commented Andrew Kucharchuk, President and Chief Financial Officer at OncBioMune. \"We had a tremendous turnout for our presentation at the LD Micro Invitational last week in Los Angeles, subsequently participating in dozens of meetings about our Company and ProscaVax. Vitel has informed us that several entities in their network are intere...